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To study important epitopes on glycoprotein E2 of Sindbis virus, eight variants selected to be singly or multiply
resistant to six neutralizing monoclonal antibodies reactive against E2, as well as four revertants which had
regained sensitivity to neutralization, were sequenced throughout the E2 region. To study antigenic determinants
in glycoprotein El, four variants selected for resistance to a neutralizing monoclonal antibody reactive with El
were sequenced throughout the E2 and El regions. All of the salient changes in E2 occurred within a relatively
small region between amino acids 181 and 216, a domain that encompasses a glycosylation site at residue 196 and
that is rich in charged amino acids. Almost all variants had a change in charge, suggesting that the charged nature
of this domain is important for interaction with antibodies. Variants independently isolated for resistance to the
same antibody were usually altered in the same amino acid, and reversion to sensitivity occurred at the sites of
the original mutations, but did not always restore the parental amino acid. The characteristics of this region
suggest that this domain is found on the surface of E2 and constitutes a prominent antigenic domain that interacts
directly with neutralizing antibodies. Previous studies have shown that this domain is also important for
penetration of cells and for virulence of the virus. Resistance to the single El-specffic neutralizing monoclonal
antibody resulted from changes of Gly-132 of El to either Arg or Glu. Analogous to the findings with E2, these
changes result in a change in charge and are found near a glycosylation site at residue 139. This domain of El
may therefore be found near the 181 to 216 domain of E2 on the surface of the El-E2 heterodimer; together, they
could form a domain important in virus penetration and neutralization.
In recent years many panels of monoclonal antibodies
(MAbs) have been isolated that are specific for the surface
proteins of viruses. Of particular interest are antibodies that
neutralize infectivity. Mechanisms of neutralization by anti-
bodies are not well understood at present, but in many cases
neutralizing antibodies are thought to exert their effect by
interfering with virus attachment to susceptible host cells.
Some neutralizing antibodies appear to bind directly to the
receptor-binding site on the virus, and anti-idiotypic antibod-
ies made to such neutralizing antibodies may function as
antireceptor antibodies (4, 9, 46). Other neutralizing antibod-
ies block binding by reacting with variable regions that are
close but not identical to the virus receptor-binding site,
because the highly conserved binding site is hidden or
protected from interaction with antibody molecules (30, 47).
Some neutralizing antibodies do not block virus attachment,
but appear to prevent penetration in some way (28). In a
number of cases, neutralizing MAbs can confer passive
protection to disease, indicating that these antibodies react
with the virus within the animal and that the epitopes
involved are immunologically important in protection
against disease (1, 18, 32, 39). The epitopes with which
MAbs react have been mapped in a number of ways,
including competitive-binding studies, use of truncated pep-
tides produced in bacteria, and study of the reactivity of
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synthetic peptides made to the amino acid sequence of the
surface proteins (12, 17, 29, 33). The last two approaches
have been of limited usefulness since many epitopes are at
least in part conformational, involving structural features
absent in short peptides or involving discontinuous portions
of the protein.
A complementary approach for mapping antigenic sites
has been to isolate virus variants which are resistant to
particular MAbs and to determine the change responsible for
the resistance (11, 15, 22, 35, 42, 45, 48). A single-amino-acid
change may confer complete resistance to neutralization by
an antibody because the amino acid involved is an important
if not dominant element of the epitope, even in the case of
dispersed or conformational epitopes. Cases have been
described, however, in which single-amino-acid substitu-
tions in regions away from the actual antibody-binding site
itself have led to escape from neutralization, because the
substitution leads to a change in conformation of the epitope
(21).
Several panels of MAbs that are reactive with the glyco-
proteins of Sindbis virus or of other alphaviruses have been
isolated (3, 18, 26, 27, 32, 33, 38, 49). As has been the case
for polyclonal antisera made to the isolated glycoproteins,
antibodies which are specific for glycoprotein El, the hem-
agglutinin, may react with both the virus and the isolated
protein and may inhibit hemagglutination by virus and
hemadsorption by infected cells, but seldom neutralize in-
fectivity. On the other hand, E2-specific antibodies are often
neutralizing. To further characterize their MAbs, Stec et al.
(40) isolated Sindbis virus variants which were resistant to
each of five different E2-specific neutralizing MAbs and to
one El-specific neutralizing MAb. In some cases, variants
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TABLE 1. Primers for sequencing the glycoproteins
Proteina Primerb 3' base cDNA sequence (5' to 3') 5' base %G+C
E3 6 8454 CATGGCCGTTACACAAACGAG 8474 52
E3-E2 RD1 8616 CCGTCTTCGTTTTCTTCG 8633 52
E2 (41-46) RD2 8749 TATTGTGGTATGCGTATG 8766 50
E2 (94-100) RD3 8911 AATCGATGTTTCCTATGA 8928 39
E2 (129-134) 9 9014 GTTCTATTTTGGTTTTAAGC 9033 33
E2 (158-163) RD4 9105 TTTCTTTGTTGACGTCCG 9122 30
E2 (228-233) RD5 9314 GATATTCTCGCTGGTTTG 9331 44
E2 (256-262) 3 9396 GTAAACGGAAAGTTCAACTA 9415 44
E2 (284-290) RD6 9487 TTAATCTATGTCTGGTGA 9504 35
E2 (350-356) 8 9686 TGTGGCTTTATCATGTCGTAAT 9706 33
E2 (386-391) RD8 9789 AATACACGGACATTTCGC 9806 33
6K (1-6) RD9 9900 CTTTGCAAGTGGCTCTGG 9918 44
6K (22-26) 20 9961 TCAACACGTATGGAAA 9976 37
El (15-21) 23 10107 ATATTCCGTGAACAACTTT 10125 32
El (58-64) 13 10238 TTTTTAGTTTACGACGCCGA 10257 40
El (130-135) 26 10449 TTTCATCCTGACGCATAA 10466 39
El (175-180) 14 10585 TAGTATTCCAGCAATAGGTA 10604 35
El (240-245) 24 10781 AACTCTACACCTTTTTG 10797 35
El (287-292) 19 10923 AAATAGTCCTGTAGTCTA 10940 33
El (371-376) 22 11191 CCCTTCTTCTGTTGTAC 11207 47
3' untranslated 25 11394 TTACTAGGCTGGTCGTT 11410 47
a Location of the primer in the protein. Amino acid residues in parentheses are numbered from the beginning of the protein.
b Primers with the prefix RD were kindly supplied by R. K. Durbin (7). Other primers were synthesized in our facility.
showed resistance to other MAbs in addition to the one with
which they were selected. Their results demonstrated the
existence of at least two independently mutable epitopes on
E2 and showed that isolates sequentially selected with more
than one antibody acquired multiple resistance. To facilitate
the analysis and rule out exogenous mutations unrelated to
antigenic reactivity, Stec et al. (40) then isolated revertants
of several of these antigenic escape variants that were once
again susceptible to neutralization by the original antibody.
To localize the changes responsible for altered antibody
reactivity, we have sequenced relevant regions of the ge-
nomic RNA of the parental AR339 strain of Sindbis virus and
of 12 variants (either singly or multiply resistant), as well as
four revertants. A preliminary description of some of these
results has appeared (42).
MATERIALS AND METHODS
Virus strains. The parental Sindbis virus from which
antigenic variants were isolated was the AR339 strain,
obtained from Joel Dalrymple. The virus was plaque purified
three times in Vero cells before isolation of antibody escape
variants. It is slightly different from the AR339 strain sup-
plied by the American Type Culture Collection (ATCC), as
described in Results. The heat-resistant strain of Sindbis
virus (HR) was originally isolated from the AR339 strain by
Burge and Pfefferkom (2). In 1972, large-plaque (LP) and
small-plaque (SP) strains of Sindbis virus HR were separated
in our laboratory. The complete sequence of Sindbis virus
HRSP RNA has been reported (41), as well as the sequence
of the structural-protein region of HRLP (24). The isolation
of Sindbis virus AR339 variants resistant to MAbs and of
revertants that were again sensitive to the selecting MAb has
been described previously (40).
RNA preparations. Seed virus stocks were prepared on
chicken embryo fibroblast monolayers as previously de-
scribed (23). For RNA preparation, two or three roller
bottles (800 cm2) were infected with virus at a multiplicity of
10 in phosphate-buffered saline (PBS) (containing Ca and
Mg) (6) with 1% fetal calf serum and 1 ,ug of dactinomycin
per ml. After a 1-h adsorption at 37°C, the inocula were
removed and replaced with Eagle medium containing 3%
fetal calf serum and 1 ,ug of dactinomycin per ml. After 3 h
at 37°C, the medium was replaced with fresh medium lacking
dactinomycin, and 1 mCi of [3H]uridine (New England
Nuclear) was added to one bottle. At 7 h after infection the
monolayers were washed with ice-cold PBS and the cells
were scraped from the glass with rubber policemen. The
cells were washed with high-salt buffer [0.5 M NaCl, 15 mM
MgCl2, 5 mM ethylene glycol-bis(P3-aminoethyl ether)-N,N,
N',N'-tetraacetic acid (EGTA), 50 mM piperazine-N,N'-bis
(2-ethanesulfonic acid) (PIPES) (pH 6.5)] and lysed with 1%
Nonidet P-40 in high-salt buffer, and the nuclei and unlysed
cells were removed by centrifugation (20). The supernatant
was made 1% in sodium dodecyl sulfate (SDS), and total
cellular RNA was prepared by phenol extraction as previ-
ously described (20, 31). After chloroform and ether extrac-
tions and multiple ethanol precipitations, the total cellular
RNA from three roller bottles was dissolved in 50 to 100 ,ul
of TE (10 mM Tris-HCl [pH 7.6], 0.1 mM EDTA) and stored
frozen at -70°C.
RNA sequencing. RNA was sequenced by the dideoxy-
chain termination method (31) modified to use reverse tran-
scriptase on RNA templates (10, 51). Avian myeloblastosis
virus reverse transcriptase was obtained from Life Sciences,
Inc. Primers were deoxyoligonucleotides 16 to 22 nucleo-
tides in length. These primers and their locations in the
Sindbis virus genomic RNA sequence are listed in Table 1.
Following the sequencing reactions, samples were run on 5%
urea-acrylamide gels 80 cm long (37) and autoradiographed
without an intensifying screen at -70°C.
Competition assays with intact and disrupted virions. Com-
petitive binding between unlabeled and horseradish peroxi-
dase (HPO)-labeled MAbs was performed as described pre-
viously (33), except that Sindbis virus antigens were
prepared in two different forms to compare the reactivities of
intact and disrupted virions. To affix intact virions to the
solid phase, we precoated wells with an antibody (MAb 49 at
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1 ,ug/ml in PBS) known to bind virion surfaces. After the
wells were blocked with 0.5% bovine serum albumin (BSA)
and rinsed with PBS, 0.25 ,ug of gradient-purified Sindbis
virus AR339 in 0.05 ml of PBS was added to each well and
adsorbed for 90 min. Wells were rinsed with PBS, and
unlabeled (competing) MAbs and HPO-labeled MAb were
added. The results of the competition were evaluated by
enzyme-linked immunosorbent assay (ELISA). Particular
efforts were made to prevent virion disruption by drying, and
the 0.02% Tween in our conventional ELISA wash solutions
was omitted from these assays. To compare disrupted viri-
ons in parallel ELISA, the same virion preparation at 2.5
mg/ml was incubated in 1% Triton X-100, diluted to 0.25
,ug/0.05 ml, and adsorbed directly to wells. The unlabeled
antibodies used in competition assays contained approxi-
mately 1 to 5 mg of MAb per ml of ascitic fluid; HPO-labeled
MAbs were used at a concentration about 10-fold above their
endpoints, i.e., at about 2 ,ug/ml.
Isolation and characterization of variants. The isolation and
characterization of the MAbs have been previously de-
scribed (32, 33). Reactivities of the variants with MAbs were
determined by ELISA and neutralization, which gave con-
cordant results (40).
RESULTS
Characterization of the MAbs used in this study. Schmal-
john et al. (32, 33) have isolated and characterized panels of
MAbs to Sindbis virus which contained both neutralizing
and nonneutralizing antibodies. For this study we have
chosen six neutralizing antibodies reactive with glycoprotein
E2 (MAbs 49, 50, 23, 18, 30, and 51) and one neutralizing
antibody reactive with glycoprotein El (MAb 33). In a
previous study with virions disrupted by drying onto an
ELISA plate, all six of these anti-E2 antibodies were found
to form a single interference group, in that all six competed
with MAb 49 for binding, whereas MAb 33 formed a distinct
interference group (33). We wished to test for competition
between these antibodies by using intact virions, that is,
under conditions similar to those that apply during neutral-
ization. For this purpose we used a capture ELISA in which
intact viriqns (AR339 strain) were first captured on the plate
by binding to fixed MAb 49 and then the ability of various
MAbs to compete with HPO-labeled MAbs for binding to
these intact virions was determined. Virions disrupted with
1% Triton X-100 and dried onto the plate were used for
comparison. The results are shown in Fig. 1. Several points
can be made from these results. (i) All six E2-specific MAbs
form a single interference group. This is particularly striking
when intact virions are used. With disrupted virus, MAbs 51
and 30 compete inefficiently with MAbs 49, 50, and 23. (ii)
The E2-specific MAbs compete with the El-specific MAb 33
for binding to intact virions but not to disrupted virions. The
converse is not always true. MAb 33 does not compete with
MAb 49 or 50, competes inefficiently with MAb 23, but
competes reasonably well with MAb 18 when intact virions
are used. With disrupted virions, MAb 33 competes only
with MAb 18. (iii) MAb 38, included as a control, is an
El-specific antibody that binds only to disrupted virions, in
which it blocks binding of MAbs 18 and 33 but not of the
others tested.
We conclude that all six E2-specific MAbs used here bind
to closely spaced or overlapping epitopes and that the
epitope recognized by the El-specific MAb 33 is found close
to these E2 neutralizing epitopes, at least in intact virus.
Interference between MAbs 33 and 18 is maintained even in
Triton-disrupted virions, for which it has been shown previ-
ously that El-E2 heterodimers are maintained (25, 50).
Reactivity of the variants with MAbs. By using this panel of
neutralizing MAbs, Stec et al. (40) isolated a number of
Sindbis virus variants. Each variant is named "v" (for
variant) followed by the number of the MAb used for
selection. Some variants were the product of sequential
rounds of selection; e.g., v23/50 was selected first with MAb
23 and then with MAb 50. (Note that this means that v23/50
and v50/23 have been independently selected for resistance
with both MAb 23 and MAb 50.) Revertants are named by
indicating which variant was used, followed by "R" and the
number of the MAb to which it has been selected to once
again be sensitive. Thus v23/50/R23 was the variant resistant
to MAbs 23 and 50, selected to again be sensitive to MAb 23.
Sindbis virus AR339 was the parental strain used for all
variants except v49, which was selected from the HRSP
strain (2). Table 2 lists the reactivities of all the variants with
a number of MAbs, as measured by ELISA. As stated
above, all of the anti-E2 MAbs used to generate resistant
variants, as well as the single anti-El MAb (MAb 33),
neutralized the infectivity of viruses with which they reacted
by ELISA (33).
Although the competitive binding experiments indicated
that the anti-E2 MAbs used here all react with the same or
closely spaced epitopes, these MAbs can be grouped as
reactive with two epitopes, termed A and B, on the basis of
the cross-reactivity of the resistant variants (Table 2). MAbs
49, 50, and 43 react with epitope A, and variants selected to
be resistant to MAb 50 are resistant to all three of these
antibodies. However, MAbs 49 and 50, both of which were
used to select variants, are not identical, as seen by their
differing reactivities with v50, v23/50/R23, and HRSP.
MAbs 23, 18, 30, and 51 react with epitope B. Certain
variants, such as v23 and vS1, are resistant to all members of
the group. Note that all of the independent isolates resistant
to MAb 23 had this pattern of reactivity. However, other
variants show complex reactivities. v30 is resistant to MAbs
30 and 51, but remains sensitive to MAbs 23 and 18.
v23/50/R23 is sensitive only to MAb 23, whereas v50/23/R49
is completely resistant only to MAb 51.
A third neutralizing epitope, termed epitope C, is defined
by MAbs R6 and R13 (5). Many of the variants were tested
for reactivity to these two MAbs and in all cases were found
to be completely sensitive, indicating that epitopes A, B, and
C are each distinct. Similarly, selection for resistance to
anti-E2 MAbs did not alter the reactivity of any variant with
anti-El or anti-capsid MAbs.
Variants resistant to MAbs 18, 30, 51, and 49 were
selected only once, but multiple independent isolates resis-
tant to MAb 23 (v23, vSO/23, and v33/50/23), MAb 50 (v50,
v23/50, and v33/50), and the anti-El MAb 33 (v33 and v23/33)
were obtained (Table 2).
RNA sequencing. To determine the changes in these vari-
ants that render the virus resistant to the various MAbs, the
glycoprotein region of viral RNAs was sequenced directly by
using a chain termination method, which has the advantage
that the nucleotide recorded at each position is the majority
nucleotide and does not arise from minor variants in the
population. Total cytoplasmic RNA from infected cells was
used as the template, and although the background with such
unpurified RNA was higher than with mRNAs selected with
oligo(dT)-Sepharose chromatography, the results were ac-
ceptable and the presence of rRNA and other RNAs in the
preparations stabilized them to long storage. The quality of
the sequence ladders was a function of the quantity of
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FIG. 1. Competition between unlabeled and HPO-labeled MAbs as assayed with intact or disrupted Sindbis virions. Virions were affixed
to ELISA plates either by antibody-mediated capture of intact virions or by direct adsorption of Triton X-100-disrupted virions. Dilutions of
unlabeled MAbs (symbols) were added to duplicate wells, followed by the HPO-labeled MAb indicated in each panel. Maximal (diluent only)
optical density (OD) values ranged from 0.45 to 1.4 and were normalized to facilitate comparisons. All MAbs used neutralize Sindbis virus
AR339, except MAb 38, which is one of several El-specific MAbs shown previously to bind to disrupted (and cell surface) viral proteins but
not to virion surfaces (33). Differences in antigenic topology are clearly evident, with apparently greater intimacy between E2 and El
neutralization epitopes in intact virions than in disrupted particles.
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TABLE 2. Reactivities of antigenic variants with MAbs
Reactivitya with Anti-E2b MAb:
Virus Reactivitya Reactivitya
variant Epitope A Epitope B Epitope Cc with Anti-El with Anti-C
MAb 33 MAb 3
49 50 43 23 18 30 51 R6 R13
AR339 100 100 100 100 100 100 100 100 100 100 100
v18 100 100 100 <50 <1 <1 <1 NDd ND 100 100
v30 100 100 100 100 100 <1 <1 ND ND 100 100
v51 100 100 ND <1 <1 <1 <1 ND ND 100 100
v5O <50 <1 <1 100 100 100 100 100 100 100 100
v23 100 100 100 <1 <1 <1 <1 100 100 100 100
v33 100 100 100 100 100 100 100 100 100 <1 100
v23/50 <1 <1 <1 <1 <1 <1 <1 ND ND 100 100
v50/23 <1 <1 <1 <1 <1 <1 <1 ND ND 100 100
v33/50 <1 <1 <1 100 ND ND 100 100 100 <1 ND
v23/33 100 100 ND <1 <1 <1 ND 100 100 <1 100
v33/50/23 <1 <1 <1 <1 <1 <1 <1 ND ND <1 100
v23/R23 100 100 100 100 100 100 100 100 100 100 100
v23/50/R23 <50 <1 <1 -80 <1 <1 <1 100 100 100 100
v50/23/R49 100 100 <50 <50 <50 <50 <1 ND ND 100 100
v50/23/R50 100 -80 -80 <1 <1 <1 <1 ND ND 100 100
HRSP 100 -80 ND <1 <1 <1 <1 100 100 100 100
v49 <1 <1 ND <1 <1 <1 <1 ND ND 100 100
Reactivities are indicated in percentages as follows: 100 indicates reactivity equal to that of the AR339 parent; -80 indicates reactivity reduced 10 to 50%,
presumably as a result of lower avidity; <50 indicates reactivity reduced more than 50%; <1 indicates a strain completely resistant to the antibody. Reactivities
were determined by ELISA, as described previously (40).
b E2 epitopes A, B, and C are separably mutable sites as determined from the patterns of cross-resistance.
c R6 and R13 are two MAbs characterized by Olmsted et al. (19).
d ND, not determined.
specific RNA present and of the oligonucleotide primers
used. Only oligonucleotide primers with a G+C content of
less than 45%, containing no mismatches, gave acceptable
results (10). A summary of all of the amino acid changes
found in the variants and their revertants is presented in
Table 3.
Variants resistant to the El-specific MAb 33. Only a single
neutralizing monoclonal antibody, MAb 33, was found that
reacted specifically with the El glycoprotein (33). Two
independent resistant variants have been selected with this
antibody, v33 (the multiple variants v33/50 and v33/50/23
were derived from v33) and v23/33. A schematic diagram of
the El glycoprotein that indicates the regions sequenced for
each of the variants is shown in Fig. 2. The locations of the
differences between the parental AR339 strain and each of
the variants are indicated. Also indicated on this figure are
sequence differences between the parental AR339 strain
used to generate the variants, the ATCC AR339 strain (16),
and the HRSP strain (41).
Both v33 (and its derivatives) and v23/33 had only a single
change in El, and both resulted in changes in Gly-132, but to
different amino acids. The sole difference within El between
the v33 series and the parental strain is the change from G to
A at nucleotide 10458, which results in the change from
Gly-132 to Arg (GGA to AGA). v23/33 has a change in a
different nucleotide in the same codon: G-10459 is replaced
with A, resulting in the change from Gly-132 to Glu (GGA to
GAA). Both changes thus result in replacement of the
uncharged Gly with a charged residue.
HRSP differs from the AR339 used to generate these
variants at four positions in El, amino acids 72, 157, 237, and
399 (Fig. 2). It is interesting that two of these differences are
shared with the AR339 strain supplied by the ATCC (16).
The AR339 strain was isolated in Egypt in 1953 (43); the
sequence data are consistent with the hypothesis that the
Dalrymple strain is a lower-passage stock than the ATCC
strain and that the substitutions at amino acids 157 and 399
occurred during passage in tissue culture.
A change from A to U at nucleotide 9987, changing Ile-30
to Phe in the 55-amino-acid protein (6K protein), was also
found in v33 and its derivatives, but is lacking in v23/33. This
change appears to be unrelated to antigenicity and is pre-
sumably an extraneous change that was fixed upon plaque
purification.
Characterization of variants resistant to neutralizing MAbs
that are reactive with E2. Figure 3 shows the regions within
E2 sequenced in all of the variants. Several have been
sequenced throughout the E2 region. For other variants,
when the pattern of alterations became clear, the sequence
of E2 has been determined only from the amino terminus
through the region in which all of the MAb-selected differ-
ences have been found (the heavily shaded domain between
amino acids 170 and 220). It seems unlikely that additional
alterations outside of the regions sequenced influence the
antigenic response of these variants. Table 3 summarizes all
of the amino acid changes found for all of the variants, with
important changes highlighted in boldface.
Variants resistant to MAb 23. Three independent variants
selected to be resistant to MAb 23 and two independent
revertants selected to be sensitive once again to MAb 23
have been examined. The resistant variants are v23 and its
derivatives v23/50 and v23/33, v50/23 and its derivatives
v50/23/R49 and v50/23/R50, and the triple variant v33/50/23.
The two independent revertants are v23/R23 and v23/50/R23.
In terms of reactivity, we can add another member to this
J. VIROL.
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TABLE 3. Amino acid changes in antigenic variants
Amino acid change in glycoproteina
Virus E2
variant 6K, El,
172 181 184 190 205 214 216 30 132
AR339 G E S K D R K I G
v18 (G) E S K D R I NDb ND
v30 (G) E L K D R K I G
v51 (G) E S K D R E I ND
v5O G E s M D R K I G
v23 G K s K D R E ND ND
v33 (G) E S K D R K F R
v23/50 G V S K D R E ND ND
v50/23 (G) E s M D R E ND ND
v33/50 (G) E s N G R K F R
v23/33 (G) E S K D R E I E
v33/50/23 (G) E s N G R N F R
v23/R23 (G) E S K D R K ND ND
v23/50/R23 G V S K D R V ND ND
v5O/23/R49c (G) E S K D R E I ND
v50/23/R50 (G) K s K D R E ND ND
HRSP R E S K D R E I G
v49d R E S K D P E ND ND
a The position of the residue in the protein is given numbered from the
amino terminus of each protein. Important changes are shown in boldface.
The nucleotide sequence encoding the amino acids given in parentheses could
not be determined unambiguously because of a compression artifact.
b ND, not determined.
c In addition to reversion to the parental Lys-190, v50/23/R49 has a change
in E2 (Gln-71 to Arg). This is the only E2 alteration found for any of the
antigenic variants characterized here that occurs outside the variable domain
between residues 170 and 220.
d The parental virus from which v49 was derived was HRSP, not AR339 as
for all other variants studied. Note that the v49 amino acids at positions 172
and 216 of E2 are the same as in the HRSP parent. Two other HRSP-specific
differences in E2 (Thr-3 to Ile and Glu-70-*Lys) are not shown since in both
cases v49 has the sequence of the parental HR. For the same reason the El
differences in amino acid positions 72, 157, 237, and 399, shown in Fig. 1, are
not listed here.
group, HRSP, which (as noted in Table 2) is also resistant to
MAb 23 and other MAbs in the epitope B group.
All of the variants resistant to MAb 23 have changes at
Lys-216 of E2. This amino acid is changed to Glu in v23 and
its derivatives (v23/33 and v23/50), in the independent isolate
v50/23 and its derivatives, and in HR. This changes the
charge at this position from positive to negative. Of the two
revertants, one (v23/R23) restores the original positively
charged Lys and the second (v23/50/R23) inserts a neutral
amino acid, Val, at residue 216. Thus, it appears that
Lys-216 of E2 is a dominant residue affecting epitope B and
that the charge of this residue is important. Note that in
v23/50/R23, Val-216 only partially restores the reactivity
with MAb 23 and fails to restore activity with MAbs 18, 30,
and 51 which also react with epitope B (Table 2).
The change in the triple variant v33/50/23 that renders the
virus resistant to MAb 23 is also a change in Lys-216, this
time to Asn. This substitution is particularly interesting: Asn
at this position creates a new asparagine-linked glycosyl-
ation site, Asn-Ile-Thr. As shown in Fig. 4, the electropho-
retic mobility of E2 from this variant is significantly altered,
suggesting that this site does indeed have an oligosaccharide
attached. Steric hindrance due to the bulky carbohydrate
moiety presumably prevents v33/50/23 from interacting with
MAb 23. A similar situation has been reported by Davis et al.
(5), in which a change at Thr-213 created a new glycosylation
site and the resulting virus was resistant to their MAb 8,
although other MAb 8-resistant variants had amino acid
substitutions at Lys-216.
It should be noted that the original MAb 23 variant, v23,
contains one additional change, a Glu-to-Lys substitution at
amino acid 181. This appears to be a change in the v23 stock
that occurred at some time after the original selection, since
it is not present in either v23/50 (in which it could have been
obscured by MAb 50-specific changes, some of which occur
at this position) or v23/33 (in which the second selection was
with an anti-El MAb). Revertant v23/R23 also has the
parental amino acid at residue 181.
Other variants in epitope B. Single variants resistant to
MAbs 18, 30, and 51 of epitope B have been examined (Table
3). v18 and v51 have substitutions for Lys-216, as did all of
the MAb 23-resistant variants. In v51 the change at position
216 is the same as that in most of the MAb 23-resistant
variants, Lys to Glu, and the patterns of cross-resistance of
v51 and v23 are identical (Table 2). In v18 the change is from
Lys to Ile, and the pattern of reactivity of this mutant with
respect to epitope B is essentially identical to that of the
revertant v23/50/R23 in which the amino acid at 216 is Val.
It is clear that amino acid 216 is an important element in
epitope B and may also be important in epitope A (see
below). Five different amino acids have been found at
residue 216 in the many variants examined, involving
changes in all three nucleotides of the codon. These are
summarized in Fig. 5.
v30 is the only epitope B variant affected at an amino acid
other than 216, and the pattern of reactivity of this variant
differs from those of the others (Tables 2 and 3). The change
Ser-184 to Leu renders the variant resistant to MAbs 30 and
51 while remaining reactive with MAbs 23 and 18. This is
also the only example in the series of resistant variants
studied here in which the substitution does not affect the net
charge of the glycoprotein.
Epitope A variants. Variants resistant to MAbs reactive
with epitope A gave a more complicated pattern of results
than did the epitope B variants. Three independent variants
selected to be resistant to MAb 50 were examined: v50 and
its derivative v50/23, v23/50, and v33/50 and its derivative
v33/50/23. v50 had a change at residue 190, Lys to Met.
v33/50 also had a change at residue 190, Lys to Asn, but had
a second change in E2 as well, Asp-205 to Gly. Both changes
may be important (see below). The third variant, v23/50, had
a change at residue 181, Glu to Val. Thus, in each case a
change in charge is involved, and residues Glu-181, Lys-190,
and possibly Asp-205 are involved in resistance to MAb 50.
Two independent revertants of v50/23 (resistance to MAb
50 as a result of the Lys-190-to-Met change) that reacquired
reactivity with MAb 50 were sequenced. v50/23/R50 was
selected with MAb 50, whereas v50/23/R49 was selected
with MAb 49. In v50/23/R49 a simple reversion back to
Lys-190 occurred. In v50/23/R50 reversion to Lys-190 also
occurred, but a second change of Glu-181 to Lys was also
found. The significance of this second change is unclear,
especially since the Glu-181-to-Val change renders the virus
resistant to MAb 50.
Results with variants resistant to MAb 49 were also
complicated. It was not possible to obtain a variant of AR339
resistant to this antibody, despite repeated attempts. How-
ever, v49 was selected by growing HRSP in the presence of
MAb 49, which indicated either that the change at position
214 from Arg to Pro, rendering the virus resistant to MAb 49,
was tolerated only in the HR background or that one or more
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FIG. 2. Schematic representation of the 6K protein and El glycoprotein genes for various strains of Sindbis virus showing the regions
sequenced and the nucleotide (and resultant amino acid [aa]) changes found. For the AR339 parent, obtained from J. Dairymple, nucleotides
numbered from the 5' terminus of the genome (41) are shown above the line for each position where a change occurs in any of the strains
shown below; below the line are shown the encoded amino acids, given in the single-letter amino acid code, numbered from the beginning
of the 6K and El proteins, respectively. Changes at the boxed Gly confer resistance to neutralization by MAb 33. Below are schematics of
various antibody escape variants, where the stippled boxes show the regions sequenced. Only nucleotides or amino acids different from
AR339 are shown; if no nucleotide or amino acid is indicated, the sequence is identical to AR339 in the first line. At the bottom are the
schematics for HRSP (41) and ATCC AR339 strain (16), showing the nucleotide and amino acid differences from the AR339 strain obtained
from Dalrymple.
of the E2 changes in HRSP distinguishing it from AR339
(positions 3, 172, and 216) are also required for resistance to
MAb 49.
Consideration of the reactivities with MAb 49 of the
variants selected for resistance to MAb 50 are illuminating in
this regard. v50 (Lys-190 to Met) is only partially resistant to
MAb 49 (Table 2). v50/23, which also has the change Lys-216
to Glu, rendering the variant resistant to MAb 23, is,
however, completely resistant to MAb 49. Similarly, v23/50
is resistant to MAb 49 and has Glu-216 (as well as a change
of Glu-181 to Val). Glu-216 is also present in HRSP. This
suggests that Glu-216 is required to obtain resistance to MAb
49 in a single step. Note that the results with v33/50 show
that Glu-216 is not essential for resistance to MAb 49, as this
variant has Lys-216. This variant does have two changes in
E2, however, Lys-190 to Asn and Asp-205 to Gly, consistent
with the hypothesis that at least two changes in the AR339
E2 sequence are required to obtain a viable virus resistant to
MAb 49.
DISCUSSION
The results with the panel of MAb-resistant variants
reported here indicate that domains in both El and E2 near
glycosylation sites are important for virus neutralization. We
assume that these domains interact directly with the neutral-
izing antibodies, although other techniques are required
before this is established with certainty. A 50-amino-acid
domain in E2 is illustrated in Fig. 6. Charged residues are
highlighted, and the highly charged nature of this domain
(25% Asp, Glu, Lys, Arg) is clear. Also clear is the impor-
tance of charged residues in the interaction with antibodies,
since all but one of the changes observed affect the net
charge. The carbohydrate attachment site at position 196 is
indicated. In all alphaviruses sequenced to date there are
carbohydrate chains attached to E2, but in only five (Sind-
bis, western equine encephalitis, Venezuelan equine enceph-
alitis, Semliki Forest, and Ross River viruses) is there a site
near residue 200. Furthermore, this domain is quite diver-
gent among the various alphaviruses. There are, however,
four conserved Cys residues (Sindbis virus E2 positions 201,
203, 220, and 226) in this domain, suggesting that there is a
defined structure in this region even if the primary sequence
is variable. The charged nature of this domain and the fact
that in five viruses it contains a carbohydrate attachment site
indicates that it is exposed on the surface of the protein,
where it can interact with the solvent, with antibodies, and
possibly with cellular receptors.
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FIG. 3. Schematic of the region encoding glycoproteins E3 and E2 to illustrate the exact regions sequenced in each case. The domains
shown as single lines were not sequenced. The heavily shaded box within E2 is the variable region in which all of the changes conferring
resistance to neutralization were found; the checkerboard box is the hydrophobic membrane spanning domain. Abbreviation: aa, amino acid.
The variability of this region is also illustrated by the fact
that in a stretch of 36 amino acids, changes in six different
residues, all but one involving a change in charge, have been
found that confer resistance to one or another of the MAbs
examined (Fig. 6). Furthermore, four other amino acids in
the 50-residue domain illustrated in Fig. 6 have been found to
vary in different strains of Sindbis virus, as shown; three of
these also involve changes in charge. Thus the sequence in
this domain is flexible in that many changes are tolerated,
including many changes in charge.
Even though two neutralization epitopes, A and B, can be
defined from the pattern of cross-reaction of resistant vari-
ants, it is clear that these epitopes are overlapping and
interrelated. First, competition experiments showed that all
A- and B-specific MAbs tested compete for binding (Fig. 1).
Second, changes in residues 184 (MAb 30) and 216 (MAbs
51, 23, and 18) render the virus resistant to B-epitope MAbs,
which overlap the changes in residues 181, 190, or 205 (MAb
50) and 214 (MAb 49) that are involved in resistance to
A-epitope MAbs. Third, it is clear that residue 216 modu-
lates the reaction of the virus with the A-epitope MAb, MAb
49, as well as being a dominant residue for interaction with
B-epitope MAbs.
The importance of residue 216 in the antigenicity of
Sindbis virus has also been found by Davis et al. (5), who
reported results with MAb 23 similar to that reported here.
In addition, they obtained one MAb (MAb 8) whose pheno-
type is the inverse ofMAb 23 in that MAb 8 requires Glu-216
6K
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FIG. 4. Virion proteins of strain AR339, v33/50t23, and other
variants analyzed by polyacrylamide gel electrophoresis (PAGE).
Purified virions were dissolved in Laemmli sample buffer under
reducing conditions and loaded directly onto 12.5% polyacrylamide
gels (13) cross-linked with N,N'-diallyltartardiamide (DATD) (34).
Molecular weights of marker proteins (in thousands) are indicated at
the left; the locations of E2, El, and the capsid protein from AR339
(C) are indicated at the right. Note that glycoprotein E2 of v33150/23
has a decreased mobility and comigrates with El.
for reactivity; variants containing Lys-216 or neutral amino
acids at residue 216 were resistant to neutralization by MAb
8.
Mapping of neutralization escape variants of other alpha-
viruses has also shown the importance of this E2 domain in
neutralization. Vrati et al. (45) found that in Ross River virus
three MAbs selected variants at positions 216, 232 to 234,
and 246 to 251. Four of six amino substitutions found
involved a change of charge. Using four MAbs, Johnson et
al. (11) found that in Venezuelan equine encephalitis virus,
there were changes at residues 182, 183, 199, and 207, two of
which involved changes of charge.
The E2 neutralization epitopes identified by the MAbs
used here, together with the El neutralization epitope iden-
tified by MAb 33, are clearly immunogenic and important for
virus neutralization. The triple variant v33/50/23 is neutral-
ized only 10% as efficiently as the wild-type virus by
anti-wild-type Sindbis virus antisera from either rabbits or
mice (33). This phenomenon is reciprocal: sera from mice
infected with v33/50/23 neutralize the variant much more
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FIG. 5. Codons and encoded amino acids at E2 residue 216 that
have been found in antigenic variants and their revertants.
efficiently than wild-type AR339 Sindbis virus (31a). The
remaining 10% of neutralizing activity that reacts with both
virus strains is presumably reactive with other epitopes.
One such additional neutralization epitope in E2 has been
identified by Pence et al. (22). These authors mapped vari-
ants of Sindbis virus resistant to epitope C MAbs and
showed that changes at residue 62, 96, or 159 were involved
(changes at 62 and 159 also involved changes in charge). This
neutralization epitope is thus distributed over disparate parts
of E2, but appears distinct from the domain defined by E2
residues 170 to 220 studied here. Using a different approach,
Stanley et al. (38) found that 10 of 12 MAbs in a panel
specific for E2 would discriminate between two strains of
Sindbis virus that differed in their neurovirulence for mice.
These two strains were later found to differ at only two
positions in E2, residues 55 and 209 (16), and both changes
(His-55 to Gln and Gly-209 to Arg) involve charge alter-
ations. The epitopes with which these MAbs react have not
been mapped, and it is unclear whether residues 55 and 209
represent contact residues for the MAbs studied by Stanley
et al. (38) or whether these two changes might induce
conformational changes within E2 or the E1-E2 heterodimer
that lead to differences in reactivity with multiple antibodies
responding to different epitopes.
The domain of E2 identified by these studies as an
important antigenic site is very likely to be involved in
binding of the virus to susceptible cells and in the virulence
of the virus. An anti-idiotypic antibody to MAb 49 appears to
function as a high-affinity antireceptor antibody in chicken
cells, and anti-idiotypic antibodies to MAbs 23 and 50 appear
to be low-affinity antireceptor antibodies (46). This suggests
that this domain plays a major role during binding of the
virus to receptors on susceptible cells. Furthermore, two
strains of Sindbis virus that differ only by having Gly or Arg
at position 172 of E2 differ in their neurovirulence for mice
(16) and in their ability to bind to cultured neuroblastoma
cells (44), consistent with the hypothesis that this domain is
important for binding to cellular receptors and suggesting
that differences in neurovirulence may arise from differences
in receptor affinities.
The work reported here has also identified a domain in El
near a glycosylation site as being important for neutraliza-
tion and presumably forming a neutralization epitope. Neu-
tralizing antibodies that interact with El are comparatively
rare. Anti-El MAbs isolated by Schmaljohn et al. (32, 33)
were mapped to five spatially distinct epitopes by competi-
tive binding studies. Only one epitope (defined by MAb 33)
led to virus neutralization, and we show here that the change
from Gly-132 to Arg or Glu renders variants resistant to this
MAb. These variants grow poorly compared with the paren-
tal virus, at least under the conditions used here to prepare
viral RNA, suggesting these changes are not neutral. The
functional unit in the virus glycoprotein spike is the E1-E2
heterodimer (8, 25, 50), and the antireceptor on the virus that
binds to the cellular receptor may be composed of domains
derived from both El and E2. The competition studies
reported here suggest that the El-specific neutralization
domain defined by MAb 33 (presumably near residue 132)
and the E2-specific neutralization domain defined by MAbs
49, 50, 23, 18, 30, and 51 (presumably the domain from 170
to 220) are spatially close in the El-E2 dimer and may form
a heterodimeric domain that binds to cellular receptors to
initiate infection. It would be of interest to examine the
neurovirulence of MAb-resistant mutants, in particular the
v33 variants, and to determine the effect of the mutations on
virus binding to various cell types.
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FIG. 6. Schematic diagram of glycoprotein E2, and an expanded view of the region containing the neutralization determinants. The amino
acid sequence of AR339 is shown, with charged residues shaded. The location of the attachment site for a complex carbohydrate chain at
residue 196 is indicated by a circle on a stem. Boxed residues are those changed in either HR (Gly-172 to Arg; Lys-216 to Glu) (41), the ATCC
strain of AR339 (Gly-209 to Arg) (16), ts2OR (Glu-200 to Lys) (14), the Ockelbo (Ock) strain of Sindbis virus (Ser-212 to Thr, Lys-216 to Glu)
(36), or antibody escape variants (Table 3). MAb 8 variants were characterized by Davis et al. (5).
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